Peritoneal Dialysis Guidelines 2019 Part 2: Main Text (Position paper of the Japanese Society for Dialysis Therapy)

Abstract Background This article is a duplicated publication from the Japanese version of “2019 JSDT Guidelines for Peritoneal Dialysis” with permission Society Dialysis Therapy (JSDT). clinical practice guideline (CPG) was developed primarily by Working Group on Revision (PD) Therapy. Recently, definition and creation process CPGs have become far more rigorous; traditional methods formats no longer adhere to current standards. To improve reliability international transmission our findings, are created in compliance methodologies Grading Recommendations, Assessment, Development Evaluation (GRADE) working group. Part 2 this PD first CPG society that conforms GRADE approach. Methods Detailed processes were accordance Cochrane handbook approach Results Clinical question (CQ)1: Is use renin-angiotensin system inhibitors (RAS inhibitors), such as angiotensin-converting enzyme (ACEI) angiotensin receptor blockers (ARB ) , effective patients? Recommendation: We suggest usage RAS (ACEI ARB) patients (GRADE 2C). CQ2: Icodextrin or glucose solution: which useful dialysate among PD? using icodextrin when managing body fluids CQ3: it better apply not mupirocin/gentamicin ointment exit site? applying sites CQ4: Which surgical desirable catheter placed, open surgery laparoscopic surgery? No recommendation. CQ5: administration route antibiotics peritonitis, intravenous intraperitoneal? intraperitoneal peritonitis Note: The National Insurance does currently cover administration. CQ6: peritoneal dialysis hemodialysis renal replacement therapy diabetic Conclusions In future, we members construct their own evidence answer CQs brought up guideline, thereby show achievements Japan worldwide.